Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension of adjunctive KarXT for schizophrenia
jRCT2041240155Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jan 2025
- Modality
- Small Molecules
01
Overview
Open-label, single-arm trial of xanomeline in schizophrenia, sponsored by Bristol Myers Squibb. Primary endpoint: Incidence of treatment-emergent adverse events. Started Jan 2025; status: completed.
02
Drugs
xanomeline
03
Conditions
schizophrenia
Beyond the preview
Go deeper on jRCT2041240155.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041240155.